Search

5th Focus in Paediatric Haematology-Oncology

The course, which is particularly aimed at specialist trainees in pediatric haemato-oncology, continued the same ethos which inspired the first four courses: the importance of close interactions between the participants and the teaching faculty, a strong emphasis on real cases…

Read more

YoungEHA featured in the European Medical Journal!

As part of a series of interviews conducted at this year’s EHA congress in Amsterdam, the European Medical Journal has published their highly insightful discussions with three distinct members: Professor Shai Izraeli, Professor Barbara Bain, and YoungEHA’s very own Dr…

Read more

King Baudouin Foundation – Calls with a relevance to hematology

The King Baudouin Foundation is an actor for change and innovation, serving the public interest and increasing social cohesion. It endeavours to maximise its impact through capacity building among organisations and people who contribute to building a better society.

Read more

Nomination criteria

General criteriaOur refreshed EHA Awards program is designed to recognize and encourage the extraordinary achievements of individuals across the field of hematology. Eligibility
To nominate or be nominated, you must be an EHA member.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

New GFI1B variants in bleeding and platelet disorders

Platelets restrict blood loss upon vessel damage by formation of a clot (thrombus). Recently, we reported a family with a bleeding and platelet disorder (BPD), which was caused by a defect in the gene GFI1B1.

Read more